Paclitaxel‐induced ST‐Segment Elevations

Gemici, Gökmen; Çinçin, Altuğ; Değertekin, Muzaffer; Oktay, Ahmet

doi:10.1002/clc.20291

Cited by 22 publications

(16 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…64-66 Profound and prolonged vasospasm has also been implied in ACS presentations of paclitaxel, gemcitabine, rituximab, and sorafenib. 37, 38, 51, 67-69 Other type II ACS (MI) scenarios can be induced by tachycardia, hypotension, hypoxia, and anemia in cancer patients with significantly reduced myocardial reserve due to coronary artery disease or potentially patho-anatomical variants such as myocardial bridging.…”

Section: Acute Coronary Syndromes (Acs)mentioning

confidence: 99%

Vascular Toxicities of Cancer Therapies

et al. 2016

View full text Add to dashboard Cite

Since the late 1990s, there has been a steady decline in cancer-related mortality, in part related to the introduction of so-called “targeted therapies”. Intended to interfere with a specific molecular pathway, these therapies have, paradoxically, led to a number of “off-target” effects. The latest examples are tyrosine kinase inhibitors targeting the Philadelphia Chromosome mutation product, which have been associated with progressive atherosclerosis and acute vascular events. Additionally, agents designed to interfere with the vascular growth factor signaling pathway have vascular side effects ranging from hypertension to arterial events and cardiomyocyte toxicity. Interestingly, the risk of cardiotoxicity with drugs such as trastuzumab is predicted by preexisting cardiovascular risk factors and disease, posing the question of a vascular component to the pathophysiology. The effect on the coronary circulation has been the leading explanation for cardiotoxicity of 5-Fluorouracil and may be the underlying the mechanism of presentation of apical ballooning syndrome with various chemotherapeutics. Classical chemotherapeutics such as cisplatin, often used in combination with bleomycin and vinca alkaloids, can lead to vascular events including acute coronary thrombosis, may be associated with an increased long-term cardiovascular risk. This review is intended to provide an update on the evolving spectrum of vascular toxicities with cancer therapeutics, particularly as it pertains to clinical practice as well as the conceptualization of cardiovascular diseases. Vascular toxicity with cancer therapy: the old and the new, an evolving avenue.

show abstract

Section: Acute Coronary Syndromes (Acs)mentioning

confidence: 99%

Vascular Toxicities of Cancer Therapies

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Na maioria dos casos, os pacientes apresentam síndrome coronariana aguda, secundária a vasoespasmo 183,[186][187][188] . O paclitaxel é utilizado para o tratamento de diversos tumores e em associação com outros quimioterápicos.…”

Section: -Taxanos (Paclitaxel/docetaxel)unclassified

I Diretriz Brasileira de Cardio-Oncologia da Sociedade Brasileira de Cardiologia

Filho¹,

Hajjar²,

Bacal³

et al. 2011

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

“…Previous cases of chest pain and electrocardiographic changes consistent with acute myocardial infarction have been reported [2-10]. Although thrombosis in situ is a potential etiology, others have proposed an “allergic myocardial infarction”.…”

Section: Introductionmentioning

confidence: 99%

Acute Myocardial Infarction in Patient With Triple Negative Breast Cancer After Paclitaxel Infusion: A Case Report

et al. 2014

View full text Add to dashboard Cite

A 47-year-old woman with breast cancer suffered progressive chest pain and flushing within 5 minutes of her second exposure to paclitaxel. Her symptoms progressed and she became pulseless. Advanced cardiac life support (ACLS) was initiated, and after a series of chest compressions the cardiac monitor revealed ventricular fibrillation. With ongoing ACLS she was transferred to the emergency department where she regained a pulse. Review of electrocardiogram revealed prominent ST elevation in leads V1, V2 and V3 with reciprocal ST depression. She was transferred urgently to the catheterization laboratory. Angiography revealed a high-grade stenosis in the proximal left anterior descending artery (LAD), and drug-eluting stents were placed without complications. She was then transferred to the floor and shortly thereafter suffered pulseless electrical activity and died despite prolonged attempts at resuscitation. Herein, we describe the development of acute myocardial infarction after paclitaxel administration, discuss potential etiologies and review evidence for an allergic component.

show abstract

Paclitaxel‐induced ST‐Segment Elevations

Cited by 22 publications

References 3 publications

Vascular Toxicities of Cancer Therapies

Vascular Toxicities of Cancer Therapies

I Diretriz Brasileira de Cardio-Oncologia da Sociedade Brasileira de Cardiologia

Acute Myocardial Infarction in Patient With Triple Negative Breast Cancer After Paclitaxel Infusion: A Case Report

Contact Info

Product

Resources

About